SCHEMBL3554315

SCHEMBL3554315

CCCCOc1ccc(S(=O)(=O)Nc2cccc(CCc3cccc(C(=O)O)c3)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 2/20 0.64
NR1H4 Q96RI1 4/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
POLB P06746 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 1/20 0.53
KAT6A Q92794 1/20 0.52
PLA2G4B P0C869 1/20 0.51
GHSR Q92847 2/20 0.50
CACNA1B Q00975 1/20 0.50
SLC16A3 O15427 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554243 0.93 MEN1 (0.60) WDR5NR1H4MEN1KMT2ATDP1
SCHEMBL3550679 0.93 WDR5 (0.57) WDR5NR1H4MEN1KMT2ATDP1
SCHEMBL3553788 0.88 POLB (0.57) WDR5POLBGHSRSLC16A3
SCHEMBL3565124 0.88 WDR5 (0.52) WDR5MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3551591 0.87 ALDH1A1 (0.65) MEN1KMT2APOLBSMN1; SMN2LMNA
SCHEMBL3561921 0.86 SLC16A3 (0.70) WDR5MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3555895 0.85 POLB (0.61) WDR5MEN1KMT2APOLBSLC16A3
SCHEMBL3558114 0.84 POLB (0.67) MEN1KMT2APOLBSLC16A3ALDH1A1
SCHEMBL3562390 0.83 POLB (0.62) MEN1KMT2APOLBSLC16A3ALDH1A1
SCHEMBL3563500 0.83 SLC16A3 (0.63) WDR5NR1H4MEN1KMT2AKAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 WDR5 1795/4885NR1H4 419/4885MEN1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.